Healthcare 02 (May 15 - Dec 25)

[winston]

7 A-rated Healthcare Stocks to Buy for the Long Term

These are some of the best names in one of the best sectors today

By Louis Navellier

Source: Blue Chip Growth

http://investorplace.com/2015/12/health ... nY_oxV96M8

[winston]

5 Guru Picks in Volatile Biotech Industry

By Sheila Dang

Source: Guru Focus

http://www.thetradingreport.com/2015/12 ... -industry/

[winston]

The One-Two Punch of Health Tech Stocks

Don’t be sitting on the sidelines of this booming industry in 2016

By Hilary Kramer

Source: Game Changers

http://investorplace.com/2015/12/health ... oiGSBV96M8

[winston]

Health care fund XLV climbs 10% since October.

[winston]

The same pill that costs $1,000 in America sells for $4 in India

Source: Bloomberg

http://thecrux.com/the-same-pill-that-c ... -in-india/

[winston]

This will be the top moneymaking trend of 2016

by Alexander Green

Synthetic biology is a new interdisciplinary branch of science, one that combines biology, biophysics, genetics and engineering.

Source: The Oxford Club

http://thecrux.com/alexander-green-this ... d-of-2016/

[winston]

Here are the top three biotech stories to watch in 2016

by Marc Lichtenfeld

Source: Lightning Trend Trader

http://thecrux.com/here-are-3-big-trend ... this-year/

[winston]

Biotech-stock fund IBB starts 2016 down around 15%.

[winston]

7 Healthcare Stocks That Are Portfolio Poison

It's imperative to know the difference between good and bad medicine

By Louis Navellier

Source: Blue Chip Growth

http://investorplace.com/2016/01/health ... view-all/#

[winston]

Singapore Healthcare - Decoupling Opportunities | POSITIVE

Maintain overweight, our top picks are Raffles Medical, Q&M and ISEC, catalysts from further expansion and more M&As.

We downgrade Cordlife to HOLD, as it has rallied significantly.

The healthcare stocks’ earnings have been resilient, but stock performances correlate with the broad market in uncertain times, diverging away from their fundamentals.

We think that current weakness caused by weaker sentiment and stake reductions by institutional investors could present buying opportunities.

Source: Kim Eng